

Attorney Docket No.: UMD-0070
Inventors: Langenfeld, John
Serial No.: 10/044,716
Filing Date: January 11, 2002
Page 11

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for the treatment of lung cancer comprising administering to a patient with lung cancer a therapeutically effective amount of a polypeptide that binds specifically to a bone morphogenetic protein-2 activity inhibitor (BMP-2) so that BMP-2 receptor activation is prevented thereby treating the lung cancer.

Claims 2-5 (canceled).

Claim 6 (currently amended): The method of claim 1 wherein the ~~bone morphogenetic protein-2 activity inhibitor~~ polypeptide that binds specifically to BMP-2 is human noggin of SEQ ID NO:4.

Claims 7-16 (canceled).

Claim 17 (original): The method of claim 1 wherein the patient is a human.

Claim 18 (currently amended): The method of claim 1 wherein the ~~bone morphogenetic protein-2 activity inhibitor~~ polypeptide that binds specifically to BMP-2 is in a composition further ~~comprises~~ comprising a pharmaceutically acceptable carrier.

Attorney Docket No.: **UMD-0070**
Inventors: **Langenfeld, John**
Serial No.: **10/044,716**
Filing Date: **January 11, 2002**
Page 12

Claim 19 (currently amended): The method of claim 18 wherein the ~~bone morphogenetic protein-2 activity inhibitor~~ polypeptide that binds specifically to BMP-2 is administered orally, enterically, ~~intravenously~~ intravenously, peritoneally, subcutaneously, transdermally, parenterally, intratumorally, or rectally.

Claims 20-64 (canceled).